Kymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform
- Thursday, March 12, 2020, 6:40
- Business
- Add a comment
CAMBRIDGE, Mass., March 12, 2020 /PRNewswire/ — Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, today announced the closing of a $102 million Series C financing. The round was led by…
About the Author
adminasapcorp has written 41802 stories on this site.